- Home
- NBIX vs SNN Comparison
NBIX vs SNN Comparison
Compare NBIX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- SNN
- Stock Information
- Founded
- NBIX 1992
- SNN 1856
- Country
- NBIX United States
- SNN United Kingdom
- Employees
- NBIX N/A
- SNN N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- SNN Industrial Specialties
- Sector
- NBIX Health Care
- SNN Health Care
- Exchange
- NBIX Nasdaq
- SNN Nasdaq
- Market Cap
- NBIX 14.4B
- SNN 15.2B
- IPO Year
- NBIX 1996
- SNN 1999
- Fundamental
- Price
- NBIX $146.61
- SNN $33.55
- Analyst Decision
- NBIX Strong Buy
- SNN Hold
- Analyst Count
- NBIX 18
- SNN 4
- Target Price
- NBIX $172.33
- SNN $32.83
- AVG Volume (30 Days)
- NBIX 1.1M
- SNN 588.2K
- Earning Date
- NBIX 10-28-2025
- SNN 10-30-2025
- Dividend Yield
- NBIX N/A
- SNN 2.18%
- EPS Growth
- NBIX 12.44
- SNN 59.91
- EPS
- NBIX 4.19
- SNN 0.56
- Revenue
- NBIX $2,682,700,000.00
- SNN $5,944,000,000.00
- Revenue This Year
- NBIX $23.68
- SNN $7.85
- Revenue Next Year
- NBIX $18.02
- SNN $5.43
- P/E Ratio
- NBIX $35.03
- SNN $60.06
- Revenue Growth
- NBIX 19.61
- SNN 5.35
- 52 Week Low
- NBIX $84.23
- SNN $23.69
- 52 Week High
- NBIX $157.67
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- NBIX 53.64
- SNN 36.87
- Support Level
- NBIX $145.00
- SNN $33.05
- Resistance Level
- NBIX $157.67
- SNN $33.60
- Average True Range (ATR)
- NBIX 5.18
- SNN 0.50
- MACD
- NBIX 0.28
- SNN -0.35
- Stochastic Oscillator
- NBIX 54.43
- SNN 33.30
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.